Marinus Pharma (MRNS) Prices 28M Share Common Offering at $1.25/Sh; Announces Concurrent Private Placement

Marinus Pharma (MRNS) Announces Elan Ezickson to Board

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced today that Elan Ezickson, has joined the Companys Board of Directors. Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic... More

After-Hours Movers 12/10: (ASPU) (OLLI) (PLAY) Higher; (ITRM) (GME) (AQST) Lower (more...)

Today's After-Hours Movers

Iterum Therapeutics plc (Nasdaq: ITRM) 38.6% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.

GameStop (NYSE:... More

Marinus Pharma (MRNS) Plans Public Offering of Common Stock and Concurrent Private Placement

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (Marinus or the Company) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Marinus also expects to grant the underwriters a 30-day option to purchase up to an... More

Marinus Pharma (MRNS) Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in TSC

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today announced clinical and regulatory updates for its orphan seizure programs in tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD) and PCDH19-related epilepsy (PCDH19-RE).

Tuberous Sclerosis Complex Program

The decision to... More

Marinus Pharma (MRNS) Highlights Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced additional data from its open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE). The results were presented at the... More